<DOC>
	<DOCNO>NCT02460770</DOCNO>
	<brief_summary>Left Ventricular Assist Devices commonly use assist fail heart bridge transplantation long-term support . The purpose MESenchymal stem cell therapy Left Ventricular Assist Device program improve heart function stem cell therapy attempt wean patient HeartMate Left Ventricular Assist Device .</brief_summary>
	<brief_title>Bone Marrow-derived Mesenchymal Stem Cells ( MSC ) Administration Weaning From Left Ventricular Assist Device</brief_title>
	<detailed_description>Currently Left Ventricular Assist Device-only patient implant follow . Feasibility autologous mesenchymal stem cell graft patient receive heart mate assess 4 patient pilot trial . Mesenchymal stem cell deliver Left Ventricular Assist Device surgery intramyocardial infusion . Recovery contractile function heart assess attempt wean patient Left Ventricular Assist Device</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Postmenopausal female female may become pregnant use adequate contraceptive precaution negative pregnancy test , Severe Left Ventricular dysfunction Ejection Fraction &lt; 30 % ischemic cardiomyopathy , New York Heart Association Class III IV , No revascularization option available , Listed cardiac transplantation , Clinical indication accept candidate Left Ventricular Assistance Device implantation destination therapy bridge transplantation , Optimal medical therapy . EXCLUSION CRITERIA : Cardiothoracic surgery within 30 day prior study entry , Myocardial infarction within 3 month prior study entry , Prior cardiac transplantation , Left Ventricular reduction surgery cardiomyoplasty , Acute reversible cause heart failure ( e.g . myocarditis , profound hypothyroidism ) , Left ventricular aneurysm wall thickness prevent cell injection , Anticipated requirement biventricular mechanical support , Stroke within 30 day prior study entry , Received investigational intervention within 30 day study entry , Pregnant breastfeeding time study entry , Human Imune deficiency Virus , Human Tcell Lymphotrophic Virus , Hepatitis B Virus Hepatitis C Virus positive within 30 day prior study entry , Active systemic infection within 48 hour prior study entry , History cancer last 5 year , Patient participant research , Patient treatment may exert inhibitory stimulatory effect growth multiplication cell , immunosuppressive property .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Left Ventricular Assist Device</keyword>
	<keyword>stem cell therapy</keyword>
	<keyword>ischemic heart failure</keyword>
</DOC>